BioCentury
ARTICLE | Product Development

Biopharma broadens fight vs. COVID-19 as Alnylam, Takeda unveil new programs

March 4, 2020 11:56 PM UTC
Updated on Mar 25, 2020 at 12:46 AM UTC

The biopharma industry is bringing additional modalities into the fight against COVID-19, with Vir and Alnylam developing an siRNA therapeutic while Takeda adds a plasma-based approach from COVID-19 survivors.

Both programs will broaden and potentially complement existing vaccine, antibody and small molecule initiatives to treat and prevent COVID-19, which currently stand at 48 vaccines and 12 therapeutics (see “Growing List of New Vaccines and Therapies in Development”)...